Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

NCT03362112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1713

Last updated 2022-04-14

Study results available
· View outcomes & findings →

Summary

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

Conditions

  • Type2 Diabetes

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-30
Primary Completion
2016-08-31
Completion
2017-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362112 on ClinicalTrials.gov